Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in more than 3000 healthy Japanese

Kosaka, Tetsuya; Yamaguchi, Masahiro; Miyanaga, Kazuo; Mizuno, Koji

doi:10.1016/s0009-8981(01)00612-x

Cited by 33 publications

(23 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Second, not only LLDs but also other medications such as aspirin, ␤-blockers, and digitalis may influence PAF-AH activity. Third, elevated PAF-AH activity indicates increased risk of CAD independently of other established risk factors, especially LDL-C. PAF-AH activity was significantly lower in women, a finding that is in agreement with findings in 3106 Japanese healthy subjects 21 and may, in general, be related to the lower cardiovascular risk found in females. In the present study, LLDs, aspirin, ␤-blockers, and digitalis affected PAF-AH activity independently, whereas LLDs had the most pronounced effect.…”

Section: Discussionsupporting

confidence: 87%

Platelet-Activating Factor Acetylhydrolase Activity Indicates Angiographic Coronary Artery Disease Independently of Systemic Inflammation and Other Risk Factors

et al. 2005

View full text Add to dashboard Cite

Background-Platelet-activating factor acetylhydrolase (PAF-AH), also denoted as lipoprotein-associated phospholipase A2, is a lipoprotein-bound enzyme that is possibly involved in inflammation and atherosclerosis. This study investigates the relationship of PAF-AH activity to angiographic coronary artery disease (CAD), the use of cardiovascular drugs, and other established risk factors. Methods and Results-PAF-AH activity, lipoproteins, sensitive C-reactive protein (sCRP), fibrinogen, serum amyloid A, and white blood cell count were determined in 2454 subjects with angiographically confirmed CAD and in 694 control subjects. PAF-AH activity was highly correlated with LDL cholesterol (rϭ0.517), apolipoprotein B (rϭ0.644), and non-HDL cholesterol (rϭ0.648) but not with sCRP or fibrinogen. PAF-AH activity was lower in women than in men and was affected by the intake of lipid-lowering drugs (Ϫ12%; PϽ0.001), aspirin (Ϫ6%; PϽ0.001), ␤-blockers (Ϫ6%; PϽ0.001), and digitalis (ϩ7%; PϽ0.001). Unlike sCRP, fibrinogen, and serum amyloid A, PAF-AH activity was not elevated in unstable angina, non-ST-elevation myocardial infarction, or ST-elevation myocardial infarction. When nonusers of lipid-lowering drugs were examined, PAF-AH activity was associated with the severity of CAD and the number of coronary vessels with significant stenoses. In individuals not taking lipid-lowering drugs and after adjustment for use of aspirin, ␤-blocker, and digitalis, the odds ratio for CAD associated with increasing PAF-AH activity was 1.39 (95% CI 1.26 to 1.54, PϽ0.001), a finding that was robust against further adjustments. Conclusions-PAF-AH activity is not an indicator of the systemic inflammation that accompanies acute coronary syndromes. PAF-AH activity is affected by a number of cardiovascular drugs; however, after such medication use was accounted for, PAF-AH activity was associated with angiographic CAD, complementary to sCRP and independently of established risk factors such as LDL cholesterol. (Circulation. 2005;111:980-987.)

show abstract

Section: Discussionsupporting

confidence: 87%

Platelet-Activating Factor Acetylhydrolase Activity Indicates Angiographic Coronary Artery Disease Independently of Systemic Inflammation and Other Risk Factors

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Second, in patients with hsCRP concentrations Ͻ10 mg/L, the additional information of LpPLA 2 activity increased the adjusted HR for cardiac death by 2-fold. LpPLA 2 activity is lower in women (17,26 ) and may, in general, be related to the lower cardiovascular risk found in females. Therefore, we made data analysis (27 ) and increased risk of stroke (28,29 ).…”

Section: Discussionmentioning

confidence: 94%

Lipoprotein-Associated Phospholipase A2 Predicts 5-Year Cardiac Mortality Independently of Established Risk Factors and Adds Prognostic Information in Patients with Low and Medium High-Sensitivity C-Reactive Protein (The Ludwigshafen Risk and Cardiovascular Health Study)

et al. 2007

View full text Add to dashboard Cite

Background: Lipoprotein-associated phospholipase A 2 (LpPLA 2 ), also denoted as platelet-activating factor acetylhydrolase, is a lipoprotein-bound enzyme involved in inflammation and atherosclerosis. In this cohort study we investigated LpPLA 2 activity to predict cardiac mortality in patients scheduled for coronary angiography. Methods: LpPLA 2 activity was determined in 2513 patients with and in 719 patients without angiographically confirmed coronary artery disease (CAD). Results: During the median observation period of 5.5 years, 501 patients died. In patients with tertiles of LpPLA 2 activity of 420 -509 U/L or >510 U/L, unadjusted hazard ratios (HRs) for cardiac death were 1.7 (95% CI 1.3-2.4; P ‫؍‬ 0.001), and 1.9 (95% CI

show abstract

“…Several studies demonstrated an increase in the activity of this enzyme with age [39][40][41][42] . The cause of this increase is perhaps related to the elevation of LDL levels that accompanies aging 43 , since a significant correlation between LDL levels and PAF-AH activity occurs 42,[44][45][46][47] .…”

Section: Resultsmentioning

confidence: 99%

Atividade da enzima acetil-hidrolase do fator ativador de plaquetas (PAF-AH) em pacientes com diabete melito tipo 1

Castro¹,

Neto²,

Gomes³

2007

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

SummaryObjective: To evaluate platelet-activating factor acetylhydrolase (PAF-AH) activity and its relationship with clinical and demographic variables, metabolic control, apolipoprotein A and B levels and the susceptibility of low-density lipoprotein (LDL) to in vitro oxidation in patients with type 1 diabetes mellitus (DM 1).Methods: Forty two patients with DM 1 (27 females) and 48 control subjects (16 females) matched for gender, age and body mass index (BMI) were evaluated. The following tests were performed: fast plasma glucose (FG) and postprandial plasma glucose (PPG), lipid profile, uric acid (UA), glycosylated hemoglobin (HbA1c), and low-density lipoprotein (LDL) oxidation rate using colorimetric assay. The PAF-AH activity was analyzed using colorimetric assay (Cayman Chemical).Results: The analysis of PAF-AH activity showed a higher enzyme activity in patients with DM 1 than in control subjects (0.0150 + 0.0051 vs. 0.0116 + 0.0041; p < 0.001). In patients with DM 1, a direct correlation between PAF-AH activity and age and LDL, and an inverse correlation between PAF-AH and HbA1c and high-density lipoprotein (HDL) were found.Conclusion: In the sample studied, PAF-AH showed a higher activity in patients with DM 1, a factor that may be related to the higher risk of developing cardiovascular diseases observed in these patients. Further studies are necessary to evaluate the real participation of this enzyme in the risk of development of atherosclerotic diseases in patients with DM 1.

show abstract

Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in more than 3000 healthy Japanese

Cited by 33 publications

References 10 publications

Platelet-Activating Factor Acetylhydrolase Activity Indicates Angiographic Coronary Artery Disease Independently of Systemic Inflammation and Other Risk Factors

Platelet-Activating Factor Acetylhydrolase Activity Indicates Angiographic Coronary Artery Disease Independently of Systemic Inflammation and Other Risk Factors

Lipoprotein-Associated Phospholipase A2 Predicts 5-Year Cardiac Mortality Independently of Established Risk Factors and Adds Prognostic Information in Patients with Low and Medium High-Sensitivity C-Reactive Protein (The Ludwigshafen Risk and Cardiovascular Health Study)

Atividade da enzima acetil-hidrolase do fator ativador de plaquetas (PAF-AH) em pacientes com diabete melito tipo 1

Contact Info

Product

Resources

About